ADAPALENE AND BENZOYL PEROXIDE Drug Patent Profile

When do Adapalene And Benzoyl Peroxide patents expire, and when can generic versions of Adapalene And Benzoyl Peroxide launch?

Adapalene And Benzoyl Peroxide is a drug marketed by Actavis Labs Ut Inc, Actavis Mid Atlantic, Alembic, Encube, Glenmark Pharms Ltd, Padagis Israel, Sun Pharma Canada, and Zydus Pharms. and is included in ten NDAs.

The generic ingredient in ADAPALENE AND BENZOYL PEROXIDE is adapalene; benzoyl peroxide. There are twelve drug master file entries for this compound. Twelve suppliers are listed for this compound. Additional details are available on the adapalene; benzoyl peroxide profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Adapalene And Benzoyl Peroxide

A generic version of ADAPALENE AND BENZOYL PEROXIDE was approved as adapalene; benzoyl peroxide by PADAGIS ISRAEL on January 23^rd, 2018.

Summary for ADAPALENE AND BENZOYL PEROXIDE

US Patents:	0
Applicants:	8
NDAs:	10
Finished Product Suppliers / Packagers:	10
Clinical Trials:	43
What excipients (inactive ingredients) are in ADAPALENE AND BENZOYL PEROXIDE?	ADAPALENE AND BENZOYL PEROXIDE excipients list
DailyMed Link:	ADAPALENE AND BENZOYL PEROXIDE at DailyMed

Recent Clinical Trials for ADAPALENE AND BENZOYL PEROXIDE

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Sun Pharmaceutical Industries, Inc.	PHASE1
University of Oklahoma	Phase 3
delta medical promotions ag	N/A

See all ADAPALENE AND BENZOYL PEROXIDE clinical trials

Pharmacology for ADAPALENE AND BENZOYL PEROXIDE

Drug Class

Retinoid

US Patents and Regulatory Information for ADAPALENE AND BENZOYL PEROXIDE

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Actavis Labs Ut Inc	ADAPALENE AND BENZOYL PEROXIDE	adapalene; benzoyl peroxide	GEL;TOPICAL	209641-001	Jun 22, 2022	AB	RX	No	No
Padagis Israel	ADAPALENE AND BENZOYL PEROXIDE	adapalene; benzoyl peroxide	GEL;TOPICAL	212464-001	May 31, 2022	AB	RX	No	No
Encube	ADAPALENE AND BENZOYL PEROXIDE	adapalene; benzoyl peroxide	GEL;TOPICAL	206164-001	May 23, 2018	AB	RX	No	No

Last updated: February 16, 2026

Market Overview

Adapalene and benzoyl peroxide combination products occupy a significant segment within the acne treatment market. They are established therapies primarily used for moderate to severe acne vulgaris. The combination improves efficacy over monotherapies, which supports sustained demand.

Market Size and Growth

The global acne medication market was valued at approximately $4.8 billion in 2022. It is projected to grow at a Compound Annual Growth Rate (CAGR) of 5.5% through 2030, reaching roughly $8 billion. The segment specifically comprising adapalene-benzoyl peroxide formulations contributes a considerable share, driven by clinical acceptance and approval of novel formulations.

Key Market Drivers

• Rise in acne prevalence among adolescents and young adults, especially in urban areas.
• Increasing awareness about acne management and cosmetic impact.
• Launch of new formulations with enhanced delivery systems.
• Growing influence of dermatology clinical guidelines favoring combination therapies.

Regional Dynamics

North America dominates with over 40% of the market due to high prescription rates and robust healthcare infrastructure. Europe follows, influenced by tightening prescription guidelines and OTC availability of some formulations. Asia-Pacific demonstrates rapid growth fueled by increasing urbanization, rising skincare awareness, and expanding pharmaceutical penetration.

Competitive Landscape

Major players include:

• Galderma (Dutasteride, Epiduo)
• Johnson & Johnson (Acanya)
• GlaxoSmithKline (Clindagel, though not a combination)
• Organic formulations from emerging biotech firms

Galderma's Epiduo (adapalene 0.1% and benzoyl peroxide 2.5%) remains the market leader, with a significant share due to strong branding and extensive distribution.

Patent and Regulatory Status

• The original patent for Epiduo expired in 2018 in the United States, leading to increased generic competition.
• Some formulations have exclusivity periods until 2025-2030 depending on regional patent laws.
• Regulatory approvals are maintained via stringent agencies (FDA, EMA), with ongoing post-market surveillance for safety.

Financial Trajectory

Revenue Trends

• In 2022, Epiduo generated approximately $1.2 billion globally for Galderma.
• The market for adapalene-benzoyl peroxide products is forecasted to sustain a CAGR of 4-6%, considering brand strength and pipeline developments.
• Generics account for around 65% of the market share in mature regions, pressuring branded prices.

Pricing Dynamics

• Average retail price per tube varies from $60 to $100, depending on formulation and region.
• Generics reduce price points by ~50%, impacting revenue distribution for patent holders.

R&D Investment

• Clinical development for new formulations or combination ratios costs approximately $20 million to $50 million per asset.
• Additional expenses include regulatory submissions, post-market studies, and lifecycle management.

Future Revenue Streams

• Biosimilar and OTC formulations could expand market access.
• Novel formulations with improved acceptability may command premium pricing.

Market Risks and Opportunities

Risks

• Patent expirations threaten revenue streams.
• Increasing OTC availability could erode prescription-based revenues.
• Competition from alternative therapies (topical antibiotics, oral therapies).

Opportunities

• Development of once-daily or sustained-release formulations.
• Personalization through targeted delivery systems.
• Expansion into emerging markets with rising acne prevalence.

Conclusion

The adapalene and benzoyl peroxide combination segment remains a profitable sphere within acne treatment markets. While patent expirations and generic competition introduce revenue pressure, ongoing innovation and market expansion counterbalance these challenges. Investment in pipeline development and geographic expansion can support continued growth.

Key Takeaways

• The global acne medication market is growing at 5.5% annually and valued at $4.8 billion (2022).
• Epiduo is the market leader, with revenues around $1.2 billion in 2022.
• Patent cliffs and OTC availability are key factors influencing future revenues.
• Emerging formulations and markets present growth opportunities.
• R&D investments continue to be essential for competitive positioning.

FAQs

Q1: When will the patent for Epiduo expire?
A1: The original patent expired in the United States in 2018; regional exclusivity varies globally, with some extending until 2025–2030.

Q2: What is the main driver behind the growth of adapalene-benzoyl peroxide products?
A2: Increasing prevalence of acne and clinical preference for combination therapies.

Q3: How does generics impact the market?
A3: Generics hold about 65% of market share in mature regions, leading to price reductions and volume-driven revenues for patent holders.

Q4: Which regions are expanding fastest?
A4: Asia-Pacific exhibits the fastest growth due to urbanization, income increases, and greater skincare awareness.

Q5: What are the main R&D considerations?
A5: Development costs range from $20 million to $50 million per product, focusing on safety, efficacy, and formulation innovation.

---

References

[1] MarketsandMarkets, "Acne Market," 2022.
[2] GlobalData, "Top Pharma Companies Report," 2023.
[3] Galderma Annual Report, 2022.
[4] FDA Drug Approvals, 2022.